1044.3500 -6.30 (-0.60%)
NSE Nov 18, 2026 15:31 PM
Volume: 228.7K
 

Deven Choksey
Alembic Pharma is expected to maintain steady growth momentum supported by its expanding complex generics portfolio in the US, sustained traction in Ex-US markets, and a gradual recovery in the domestic formulations business.
Number of FII/FPI investors increased from 179 to 189 in Sep 2026 qtr.
More from Alembic Pharmaceu…
All earning calls
Investor presentations from Alembic Pharmaceu…
All investor presentations